Physician profile
Wasif Riaz
NPI 1497929319
$24,649.84
in general payments reported to CMS, 2019-2025
89 companies · $5,542 in 2025
The $5,542 reported for 2025 was more than what 75% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,213 · 2020: $1,505 · 2021: $2,491 · 2022: $3,317 · 2023: $4,496 · 2024: $5,086 · 2025: $5,542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $989.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,134.41 |
| Education | $988.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,171.05 | 2019-2025 | Tecvayli, Darzalex, Rybrevant |
| Pfizer INC. | $1,688.52 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,609.69 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,403.88 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Astrazeneca Pharmaceuticals LP | $1,344.37 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Celgene Corporation | $1,309.75 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Astellas Pharma US INC | $1,154.67 | 2019-2025 | Vyloy, Xtandi, Padcev |
| Merck Sharp & Dohme LLC | $1,088.37 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Seagen INC. | $808.26 | 2019-2023 | Tukysa, Tivdak, Adcetris |
| Lilly USA, LLC | $733.65 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Gilead Sciences, INC. | $689.08 | 2021-2025 | Trodelvy |
| Daiichi Sankyo INC. | $598.31 | 2021-2025 | Enhertu, Datroway, Vanflyta |
| Amgen INC. | $584.37 | 2019-2022 | |
| Abbvie INC. | $528.56 | 2019-2025 | |
| Genentech USA, INC. | $510.45 | 2019-2025 | Tecentriq, Alecensa, Polivy |
Show all 89 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wasif Riaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.